ALPMY - Astellas Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
3/30/2019
3/30/2018
3/30/2017
3/30/2016
Total Revenue
1,309,722,000
1,306,348,000
1,300,316,000
1,311,665,000
1,372,706,000
Cost of Revenue
287,383,000
292,050,000
294,250,000
320,503,000
335,596,000
Gross Profit
1,022,339,000
1,014,299,000
1,006,066,000
991,162,000
1,037,110,000
Operating Expenses
Research Development
214,090,000
208,682,000
220,781,000
208,129,000
225,665,000
Selling General and Administrative
484,800,000
490,263,000
478,330,000
470,777,000
500,359,000
Total Operating Expenses
740,645,000
768,760,000
790,388,000
728,467,000
786,881,000
Operating Income or Loss
281,694,000
245,539,000
215,678,000
262,695,000
250,229,000
Interest Expense
2,601,000
1,302,000
1,782,000
1,976,000
1,627,000
Total Other Income/Expenses Net
-
-
-
-
-
Income Before Tax
282,253,000
248,967,000
218,113,000
281,769,000
261,770,000
Income Tax Expense
35,326,000
26,702,000
53,434,000
63,069,000
68,083,000
Income from Continuing Operations
246,927,000
222,265,000
164,679,000
218,700,000
193,687,000
Net Income
246,925,000
222,265,000
164,679,000
218,701,000
193,687,000
Net Income available to common shareholders
246,925,000
222,265,000
164,679,000
218,701,000
193,687,000
Reported EPS
Basic
-
115.05
81.11
103.69
89.75
Diluted
-
114.94
81.02
103.55
89.62
Weighted average shares outstanding
Basic
-
1,931,882
2,030,203
2,109,149
2,158,131
Diluted
-
1,933,748
2,032,472
2,111,979
2,161,306
EBITDA
-
313,727,000
284,758,000
347,536,000
332,585,000